Deepika Jalota

Prior to joining PMV Pharma, Dr. Jalota was Vice President, Head of Global Regulatory Strategy, Oncology I at Bayer HealthCare Pharmaceuticals where she was responsible for overseeing the development of global regulatory strategies for several early and late stage oncology projects, including Xofigo®, VITRAKVI® and darolutamide. From 2014-2016 at Bayer, she was responsible for overseeing the development of global regulatory strategies in Ophthalmology and Dermatology, including Eylea®.

Prior to working at Bayer for 12 years, Dr. Jalota was employed with Sanofi-Aventis, Forest Laboratories and Procter and Gamble Pharmaceuticals within various roles across drug development.

Dr. Jalota received her Pharm.D. from University of Florida, College of Pharmacy, and her B.S. in Pharmacy from Rutgers University, Ernest Mario School of Pharmacy.